普罗布考联合依帕司他治疗早期糖尿病性肾病的疗效观察

目的观察普罗布考联合依帕司他治疗早期糖尿病性肾病(DN)的疗效。方法选取2014年1月至2016年1月于中关村医院就诊的55例早期DN患者随机分为治疗组和对照组。两组患者均在给予优质低蛋白糖尿病饮食、控制血糖、血压达标的基础上,治疗组口服依帕司他(50 mg,3次/d)和普罗布考(0.5 g,2次/d);对照组仅口服普罗布考(0.5 g,2次/d)。两组均随访24周。结果两组患者治疗后血肌酐(SCr)、超敏C反应蛋白(hs-CRP)、尿白蛋白排泄率(UAER)均降低(P0.05);且治疗组较对照组下降更为明显(P0.05)。结论普罗布考与依帕司他联合应用能更有效地降低早期糖尿病患者尿蛋白水平。

Efficacy of probucol combined with epalrestat in the treatment of early diabetic nephropathy: report of 55 cases

Objective To observe the therapeutic effects of probucol combined with epalrestat in the treatment of early diabetic nephropathy (DN). Methods A total of 55 cases of early DN admitted in Zhongguancun Hospital from January 2014 to January 2016 were recruited in this study. They were divided randomly into 2 groups, the treatment group (50 mg epalrestat, tid and 0.5 g probucol, bid) and the control group (only 0.5 g probucol, bid). The 2 groups of patients were given diabetic diet with low protein, and kept well control of blood glucose and blood pressure. The 2 groups were treated for 24 weeks and some indicators were measured to evaluate the therapeutic results. Results The serum levels of creatinine (SCr), hyper-sensitivity C-reactive protein (hs-CRP) and urinary albumin excretion rate (UAER) were all reduced in the both groups after the treatment (P<0.05). The above indicators were decreased more significantly in the treatment group than in the control group (P<0.05). Conclusion Probucol combined with epalrestat is superior to single use of probucol in decrease of proteinuria in the patients with early DN.